The FDA’s gag rule on off-label treatments

Of Consuming Interest

The FDA’s gag rule on off-label treatments

Michael Cannon of the Cato Institute talks about restrictions on discussing legal uses of drugs for off-label purposes.

Shirley Rooker

July 7, 2019 10:53 am

< a min read

Michael Cannon, director of health policy studies for the Cato Institute, talks about the gag rule that places restrictions on discussing legal uses of drugs for off-label purposes, as well as a bill that would make trial drugs available to terminally ill patients.